Last reviewed · How we verify
pneumococcal 23v polysaccharide vaccine
This vaccine stimulates the body's immune response to produce antibodies against pneumococcal serotypes.
This vaccine stimulates the body's immune response to produce antibodies against pneumococcal serotypes. Used for Prevention of invasive pneumococcal disease caused by Streptococcus pneumoniae serotypes included in the vaccine.
At a glance
| Generic name | pneumococcal 23v polysaccharide vaccine |
|---|---|
| Also known as | V110, PNEUMOVAX |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The pneumococcal 23v polysaccharide vaccine contains 23 different capsular polysaccharides from Streptococcus pneumoniae. These polysaccharides are used to stimulate the body's immune response, which then produces antibodies to fight off pneumococcal infections.
Approved indications
- Prevention of invasive pneumococcal disease caused by Streptococcus pneumoniae serotypes included in the vaccine
Common side effects
- Injection site pain
- Fatigue
- Headache
- Fever
- Malaise
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: